Caris Life Sciences has introduced Caris MI Clarity™, an AI-powered prognostic test that assesses both early and late distant recurrence risks for postmenopausal patients with HR-positive/HER2-negative, node-negative early-stage breast cancer. The test uses AI to analyze routine pathology slides and clinical data, delivering results within three business days, much faster than traditional methods. This innovation helps doctors better personalize treatment by understanding how recurrence risk evolves over time, potentially improving patient outcomes and reducing overtreatment or undertreatment. The test's development involved extensive validation with national clinical trial data, marking a significant advancement in breast cancer risk assessment and management.
Daniel Jones, leader of the Daniel Jones Investing Group, advises selling the Schwab US Dividend Equity ETF (SCHD) because it consistently underperforms compared to market indices and carefully selected high-yield portfolios. Despite SCHD's attractiv...
Wall Street ended the holiday-shortened week higher, driven by optimism over a potential Federal Reserve interest rate cut by year-end despite weaker-than-expected June jobs data. Technology stocks rebounded early in the week amid easing U.S.-Iran te...
Ethereum's price recovered past the $1.7K resistance, rising 3.02% to $1,756, driven by strong momentum indicators like MACD and RSI. A major whale closed a $54.1 million short position, taking a $9.386 million loss and paying $36,000 in fees, reflec...
Kimberly-Clark reported broad organic sales growth driven by volume and mix, though pricing pressures persist due to low consumer sentiment. While energy prices have normalized, consumers remain value-focused, limiting pricing power. Concerns over in...
Prediction markets indicate a 70% probability that XRP will close July 2026 above $1.20, reflecting bullish sentiment despite limited upside beyond this level. Currently trading around $1.14, XRP has gained about 8.5% since early July. Traders assign...
